TerminatedNot Applicable

Duration of Medication Therapy and Outcomes After Holmium Laser Prostate Surgery for Patients With Benign Prostatic Hyperplasia (BPH)

Stopped: Slow recruitment of patients who have been on medication for under a year for benign prostatic hyperplasia

United States144 participantsStarted 2018-11-15

Plain-language summary

To determine if the prior prolonged use of medication, as a treatment for benign prostatic hyperplasia, reduces the efficacy of Holmium laser enucleation of the prostate (HoLEP) for patients with benign prostatic hyperplasia (BPH).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients must be 18 years of age or older
✓. Patients must present to clinic with a diagnosis of benign prostatic hyperplasia with lower urinary tract symptoms
✓. Patients must be scheduled to undergo a holmium laser prostate surgery (enucleation or ablation)

Exclusion criteria

✕. Patients who are under 18 years of age are not eligible.
✕. Patients who have a diagnosis of bladder cancer are not eligible.
✕. Patient who have a diagnosis of prostate cancer are not eligible.
✕. Patients with an elevated prostate-specific antigen (PSA) suggesting prostate cancer are not eligible unless patient has prior negative prostate biopsy.
✕. Patients who have acute prostatitis, a prostate abscess, or neurogenic bladder are not eligible

What they're measuring

Bladder Function

Timeframe: Six Months

Trial details

NCT IDNCT03768765

SponsorUniversity of Kansas Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-06-19

View on ClinicalTrials.gov More Benign Prostatic Hyperplasia trials